In the new era, the development of pharmaceutical manufacturing is an important part of "promoting the construction of a healthy China", and it is essential to develop the independent R&D and innovation capabilities of the domestic pharmaceutical companies.The government has formulated a number of policies and measures to regulate and support the pharmaceutical industry, which has helped the pharmaceutical industry make great progress in raw material drugs and generic drugs.However, due to the fact that the pharmaceutical manufacturing industry has a long R&D cycle and a high entry threshold, the scientific discovery and industrial technology correlation degree is high, resulting in insufficient pharmaceutical innovation capability, especially in new drugs, special drugs, bio-pharmaceuticals, etc.So how can the pharmaceutical manufacturing industry enhance its innovation capability and thus improve the innovation performance of companies? Existing literature studies the innovation capability of pharmaceutical manufacturing industry from the perspective of science-based innovation and technology-based innovation, but most of the studies classify the pharmaceutical manufacturing industry into the science-based industry, and fail to cover the whole pharmaceutical manufacturing industry; furthermore, the science-based innovation and technology-based innovation may be accomplished in a large-scale enterprise jointly with scientific research institutes, which introduces the questions if there is a feedback mechanism or interaction between science and technology within the enterprise, and how this interaction affect innovation performance.#br#From the perspective of innovation capability structure, this paper selects 142 listed pharmaceutical manufacturing companies, introduces the enterprise-science correlation index (ESCI) and enterprise-technology correlation index (ETCI) to classify the companies into dual, professional and other types of organizations, and conducts multiple regression analyses for dual organizations and professional organizations.Multiple regression analyses are conducted to verify the effects of scientific and technological relevance and their interactions on innovation performance in different types of organizations.#br#The results show that "enterprise-science correlation" and "enterprise-technology correlation" have significant positive effects on innovation performance in both dual and professional organizations.The interaction of the two types of innovation activities has a significant positive effect on innovation performance in dual-type organizations.In professional organizations, the interaction of the two types of innovation activities has a significant negative effect on innovation performance.For pharmaceutical companies with large scale and sufficient dual innovation capability, in order to maintain their competitive advantages, they need to select and realize popular targets while continuing to carry out pharmaceutical process innovation, earn profits with high-quality first-investigation drugs, and further feed back to the scientific research of innovative drugs, so that the interaction between science-based and technology-based innovations can form a virtuous cycle of positive feedback in the companies.For professional pharmaceutical companies led by scientific innovation, in the early stage of development, they can improve their own technological innovation capability through production technology cooperation with other companies, so as to realize the evolution to a large-scale dual-type organization.For professional pharmaceutical companies led by technological innovation, they can choose drugs with certain technical barriers for imitation to realize the transition to dual organizations.For most small and medium-sized pharmaceutical companies that are unable to construct a dual innovation organization in the short and medium term, they can make use of external scientific and technological resources to enhance their innovation capability and performance through in-depth industry-university-research institution cooperation.#br#This study incorporates the research on science-based and technology-based innovation at the industrial level into the enterprise level, structurally disassembles the innovation capability of pharmaceutical manufacturing companies, and provides new perspectives and new ideas for targeted improvement of innovation performance of pharmaceutical companies with different levels of innovation in China.While the existing industry-level literature on science/technology-based innovation mostly stays in the description of cases and the determination of concepts, this study selects typical listed companies in the pharmaceutical industry and empirically analyzes the impact of ESCI,ETCI, and their interactions on the innovation performance of companies, thus enriching the theory of science- and technology-based innovation at the enterprise micro level.#br#
Dai Yong
,
Zhang Qiuxuan
,
Zhu Guilong
. How Do ESCI and ETCI Affect the Innovation Performance of Pharmaceutical Companies?[J]. Science & Technology Progress and Policy, 2023
, 40(19)
: 96
-105
.
DOI: 10.6049/kjjbydc.2023040264
[1] JIANG Q, LUAN C.Diffusion, convergence and influence of pharmaceutical innovations: a comparative study of Chinese and U.S.patents[J].Globalization and Health, 2018, 14(92): 1-9.
[2] 于赫,王晓颖.技术并购对企业创新能力的影响——来自医药企业的实证研究[J].工业技术经济,2021,49(12):25-34
[3] 刘志迎,支援援,吴瑞瑞.开放获取资源能够促进二元创新吗[J].东北大学学报( 社会科学版),2021,23(1):24-33
[4] 曾德明,罗侦,文金艳,等.权变视角下知识重组对技术创新质量的影响——基于中国医药制造业企业的实证研究,管理评论,2022,34(9):87-97.
[5] 赖红波,施浩.技术体制与医药制造业创新效率研究[J].科研管理,2021,42(11):16-24.
[6] 汪涛,王璐玮,张晗.中国城市新兴技术的双元创新路径与发生机制——以生物医药技术为例[J].科技进步与对策,2022,39(6):29-39.
[7] CORIAT B.Does biotech reflect a new science-based innovation regime[J].Industry & Innovation, 2003,10(3): 231-253.
[8] 鲁若愚,张立锴,陈雪琳.基于科学的产业发展影响因素组态与路径研究——对中国内地31省份医药制造业的QCA分析[J].科技进步与对策,2022, 39(16):20-28.
[9] 董坤,许海云,罗瑞,等.科学与技术的关系分析研究综述[J].情报学报, 2018,37(6):642-652.
[10] 肖丁丁,朱桂龙.跨界搜寻、双元能力结构与绩效的关系研究——基于创新能力结构视角[J].经济管理, 2017, 39(3):48-62.
[11] 李欣融,张庆芝,雷家骕.基于科学的创新:研究回顾与展望[J].科研管理,2022,43(1):1-13.
[12] PISANO G P.Knowledge, integration, and the locus of learning: an empirical analysis of process development [J].Strategic Management Journal,2006, 15(S1):85-100.
[13] NAGAOKA S.Assessing the R&D management of a firm in terms of speed and science linkage: evidence from the US patents [J].Journal of Economics & Management Strategy,2007,16(1): 129-156.
[14] ARTHUR W B.The structure of invention [J].Research Policy, 2007,21(29): 10436-10442.
[15] BECKMAN C M.The influence of founding company affiliations on firm behavior [J].Academy of Management Journal, 2006,49(4):741-758.
[16] BIERLY P E, DALY P S.Alternative knowledge strategies, competitive environment, and organizational performance in small manufacturing firms [J].Entrepreneurship Theory & Practice, 2007,31(4):493-516.
[17] DOVEV L, URIEL S.Exploration and exploitation within and across organizations [J].Academy of Management Annals, 2010,4(1):109-155.
[18] HE Z L, WONG P K.Exploration VS.exploitation: an empirical test of the ambidexterity hypothesis [J].Organization Science, 2004,15(4): 481-494.
[19] STETTNER U, LAVIE D.Ambidexterity under scrutiny: exploration and exploitation via internal organization, alliances, and acquisitions[J].Strategic Management Journal, 2014,35(13):1903-1929.
[20] GUPTA A K, SHALLEY C E.The interplay between exploration and exploitation[J].Academy of Management Journal, 2006,49(4):693-706.
[21] BENNER M J, TUSHMAN M L.Exploitation, exploration, and process management: the productivity dilemma revisited[J].Academy of Management Review, 2003,28(2):238-256.
[22] 李天柱,银路,程跃.美国生物制药企业的发展路径研究及其启示[J].中国软科学,2010,35(5):136-142.
[23] 刘海建,吴通.恒瑞医药:跨越创新的陷阱与断层[J].清华管理评论,2021,12(1):132-143.
[24] MEYER M.Does science push technology? patents citing scientific literature[J].Research Policy, 2000,29(3):409-434.
[25] HARHOFF D, SCHERER F M.Citations, family size, opposition and the value of patent rights[J].Research Policy,2003, 32 (8): 1343-1363.
[26] THOMAS P, MCMILLAN G S.Using science and technology indicators to manage R&D as a business[J].Engineering Management Journal, 2015, 13(3): 9-14.
[27] TIJSSEN R.Global and domestic utilization of industrial relevant science: patent citation analysis of science-technology interactions and knowledge flows[J].Research Policy,2001, 30 (1): 35-54.
[28] WU C Y, MATHEWS J A.Knowledge flows in the solar photovoltaic industry: insights from patenting by Taiwan, Korea and China[J].Research Policy, 2012,41(3): 524-540.
[29] DEDRICK J,KRAEMER K L.Who captures value from science-based innovation? the distribution of benefits from gmr in the hard disk drive industry[J].Research Policy, 2015,44(8): 1615-1628.
[30] GIULIANI E.Cluster absorptive capacitywhy do some clusters forge ahead and others lag behind[J].European Urban & Regional Studies, 2005,12(12):269-288.
公众号